Autonomix Medical Faces Delisting Concerns

TL;DR

Autonomix Medical might get delisted, stock watch!

AI Summary

Autonomix Medical, Inc. filed an 8-K on September 20, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principal executive offices are located at 21 Waterway Avenue, Suite 300, The Woodlands, TX 77380. The report was filed as of September 20, 2024, with the earliest event reported on September 16, 2024.

Why It Matters

This filing indicates potential delisting from a stock exchange, which could significantly impact the company's stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

• Autonomix Medical, Inc. (company) — Registrant
• 21 Waterway Avenue, Suite 300, The Woodlands, TX 77380 (location) — Principal executive offices
• September 16, 2024 (date) — Earliest event reported
• September 20, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock , par value $0.001 per share AMIX The Nasdaq Stock Mark
• $1.00 — mmon stock had closed below the minimum $1.00 per share requirement for continued inc

Filing Documents

• amix20240917_8k.htm (8-K) — 28KB
• pic1.jpg (GRAPHIC) — 2KB
• 0001437749-24-029752.txt ( ) — 167KB
• amix-20240916.xsd (EX-101.SCH) — 3KB
• amix-20240916_def.xml (EX-101.DEF) — 12KB
• amix-20240916_lab.xml (EX-101.LAB) — 15KB
• amix-20240916_pre.xml (EX-101.PRE) — 12KB
• amix20240917_8k_htm.xml (XML) — 3KB

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 16, 2024, Autonomix Medical, Inc. (the "Company") received a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that for the last 30 consecutive business days the closing bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). The deficiency letter does not result in the immediate delisting of the Company's common stock from the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the "Compliance Period Rule"), the Company has been provided an initial period of 180 calendar days, or until March 17, 2025 (the "Compliance Date"), to regain compliance with the Bid Price Rule. If, at any time before the Compliance Date, the closing bid price for the Company's common stock closes at $1.00 or more for a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Bid Price Rule, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company is not in compliance with the Bid Price Rule by March 17, 2025, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the minimum bid price deficiency, which may include, if necessary, implementing a reverse stock split.

View Full Filing

View this 8-K filing on SEC EDGAR